Stop worrying about overage! HPV Nine-Valent Age Extension: Down to 9 years old to 45 years old, how can women better protect themselves in all aspects?

Recently, merck nine-valent human papillomavirus vaccine (hereinafter referred to as "nine-valent HPV vaccine") has been approved by the State Food and Drug Administration, and the applicable population in China has expanded from 16-26-year-old women to 9-45-year-old women

"Age extension" is a strong and targeted protection

Clinical data show that the incidence of cervical cancer in China is increasing year by year, and the incidence is showing a trend of rejuvenation, which seriously affects the health

At present, bivalent and quadrivalent HPV vaccines cover two high-risk types of HPV16 and 18, but the International Agency for Cancer Research's analysis of HPV infection worldwide shows that HPV infection types are distributed in different regions and different populations, "The high-risk hpvic types that Women in China are most susceptible to infection also include 52 and 58 types, in layman's terms, the nine-valent prevention effect is better, not only covering 9 types including these four high-risk types, which can prevent about 92% of cervical cancer, but also covers low-risk hpv6 and 11 types.

In addition, unlike foreign countries, the HPV infection rate of female people in China changes with age, and there are two infection peaks, "which are 14-24 years old and 41-45 years old.

China's nine-valent HPV vaccine, the severe challenge of vaccination

Urban women around the age of 20-30 are generally vaccinated against HPV, but the real data is not optimistic, and The Lancet has published a study on the reproductive, maternal, newborn, child and adolescent health of women in China in 70 years, entitled "A Lancet Commission on 70 years of women's reproductive, maternal, newborn, child, and adolescent.

Figure Research Results (Source: [2])

Cancer is the leading cause of premature death and disability worldwide, especially among

Figure Incidence and mortality of breast and cervical cancer in women in some countries and regions (Source:[2])

One of the challenges facing China is the low

The screening rate for cervical cancer in women over the age of 21 is only 21.

Since 2009, such screenings have been available free of charge in two cancer screening programs in 286 poor counties, and expanded to more than 1,700 counties in 2018 (including breast cancer screening for 48 million women and cervical cancer screening for 120 women), an approach that does not seem sufficient to encourage most women to be screened

On July 31, 2017, China announced that it would provide human papillomavirus (nine-valent HPV vaccine)

■ Delayed application of HPV vaccine

Since 2006, HPV vaccines have been licensed and successfully used

■ Chinese people's understanding of HPV vaccine is still insufficient

Since the official introduction of the HPV vaccine in China in 2016, public awareness and understanding of it remains low

■ The recommended age for HPV vaccination has been extended

Since the optimal time for HPV vaccination is before sexual activity begins, the main target population recommended by the WHO is girls aged 9-14 years; In contrast, the recommended age for the old government is 16-26 years for the 9-valent HPV vaccine, 20-45 years for the 4-valent HPV vaccine, and 9-45 years for the 2-valent

■ HPV vaccine supply shortage

HpV vaccines are reportedly in short supply

■ HPV vaccines are expensive

Currently, in community health centers, a dose of the 9-valent HPV vaccine costs at least $1,300 (about $4,000 for three doses in

Another concern: While screening can provide better treatment opportunities for young women by diagnosing more reproductive cancers at an early stage, some treatments may affect the reproductive organs and induce gonadal failure

HPV vaccination is not "once and for all"

In principle, regular cervical cancer screening
is required for all women who have already had sex, regardless of whether they have been vaccinated against HPV.
There are many subtypes of HPV, of which more than 10 can cause cervical cancer, namely "high-risk types"
.
About 70% of cervical cancers are introduced by two subtypes of HPV16 and 18, and bivalent and quadrivalent HPV vaccines can prevent these two subtypes; In addition to HPV16 and 18, the nine-valent vaccine can also prevent five subtypes of 31, 33, 45, 52 and 58, and can prevent about 92% of cervical cancer
.
For other high-risk HPV, the current vaccine is still beyond the reach of the
whip.

Therefore, after receiving HPV vaccine, cervical TCT and HPV screening should be carried out regularly, which can effectively prevent cervical cancer and nip cervical cancer in the bud in time
.

So, is it necessary for men to get the HPV vaccine? Although hpv vaccination is not open to men in China, it does not mean that men do not have the need to
fight HPV.
Men are vaccinated against HPV, on the one hand, to protect themselves, and on the other hand, to protect themselves, on the other hand, for the health of
their loved ones.

Many people will think that the HPV vaccine is only meaningful for cervical cancer in women, but in fact, the HPV virus not only causes cervical cancer, but also closely related to 50% of penile cancer, 20% of oral cancer, 90% of anal cancer and genital warts
.
You read that right! The HPV virus not only infects women, but also infects men "rain and dew", and can also bring cancer and genital lesions
.

After infection with HPV, patients may not be aware of it at all, and there are no symptoms after infection, so many people transmit HPV to people who
have intimate relationships without their knowledge.
At present, there is no specific drug for the treatment of HPV, if unfortunately, it can only be treated for symptoms, and the HPV virus itself can only wait for the body to clear
itself.
Before the body clears, if it is repeatedly infected, it is very likely to develop into a malignant tumor
.
Therefore, it is also necessary for men to get the HPV vaccine
.

Resources:

[1]https://jsnews.
jschina.
com.
cn/nj/a/202209/t20220902_3067990.
shtml

[2] Qiao J, Wang Y, et al.
A Lancet Commission on 70 years of women's reproductive, maternal, newborn, child, and adolescent health in China.
Lancet.
2021 Jun 26; 397(10293):2497-2536.
doi: 10.
1016/S0140-6736(20)32708-2.
Epub 2021 May 24.
PMID: 34043953.

[3]https://mp.
weixin.
qq.
com/s/QaIyEAzksLw8jZX_WJ_4YQ

[4]